Insider Transactions in Q1 2021 at Poseida Therapeutics, Inc. (PSTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
57,060
-0.75%
|
$627,660
$11.54 P/Share
|
|
Mar 01
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
57,940
-0.38%
|
$637,340
$11.89 P/Share
|
|
Feb 23
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
111,395
+17.02%
|
$111,395
$1.17 P/Share
|
|
Feb 16
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
133,149
-39.88%
|
$1,331,490
$10.0 P/Share
|
|
Feb 10
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
12,389
-3.58%
|
$123,890
$10.0 P/Share
|
|
Feb 10
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
67,534
+13.53%
|
$67,534
$1.29 P/Share
|
|
Jan 21
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
4,462
-1.27%
|
$44,620
$10.0 P/Share
|
|
Jan 15
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,564
+39.71%
|
$7,564
$1.32 P/Share
|
|
Jan 15
2021
|
Johanna Mylet Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,728
+14.99%
|
$0
$0.3 P/Share
|
|
Jan 08
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,921
+50.0%
|
$3,921
$1.32 P/Share
|